deltatrials
Completed PHASE3 NCT00002446

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Sponsor: Schering-Plough

Conditions Candidiasis, Oral HIV Infections
Interventions Fluconazole Posaconazole
Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Aug 31, 1998

A PHASE3 clinical study on Candidiasis, Oral and HIV Infections, this trial is completed. The trial is conducted by Schering-Plough and has accumulated 6 data snapshots since 1998. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Schering-Plough
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berkeley, United States, Brooklyn, United States, Camden, United States, Charleston, United States, Chicago, United States, Dallas, United States, Denver, United States, Detroit, United States, Indianapolis, United States, Jacksonville, United States and 7 more location s